Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Venous Thrombosis 1Venous Thromboembolism 1Thromboembolism 1Pulmonary Embolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Sorafenib 42Bevacizumab 16Oxaliplatin 13Radiosurgery 10Gemcitabine 10Doxorubicin 10Capecitabine 10Leucovorin 9Hepatectomy 9Fluorouracil 9Cisplatin 9Radiofrequency Ablation 8Nivolumab 8pembrolizumab 7Drug Therapy 7Carboplatin 7Irinotecan 6Cryosurgery 6Talaporfin 5Mitomycin 5Everolimus 5Erlotinib Hydrochloride 5Electroporation 5spartalizumab 4Sunitinib 4Melphalan 4Ipilimumab 4Epirubicin 4Embolization, Therapeutic 4regorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Neoplasms × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡